SCHEMBL14415286

SCHEMBL14415286

CN(C)C1CCN(c2ccc(NC(=O)N3CCN(c4ccc(Cl)cc4Cl)CC3)cc2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 7/20 0.56
▸ CA12 O43570 2/20 0.51
▸ CA2 P00918 2/20 0.51
▸ CA9 Q16790 2/20 0.51
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ MAPT P10636 4/20 0.50
▸ FPR1 P21462 2/20 0.49
▸ FPR2 P25090 2/20 0.49
▸ HTR1A P08908 1/20 0.48
▸ HTR1D P28221 1/20 0.48
▸ HTR1B P28222 1/20 0.48
▸ HTR2A P28223 1/20 0.48
▸ HTR2C P28335 1/20 0.48
▸ HTR6 P50406 1/20 0.48
▸ TP53 P04637 2/20 0.47
▸ POLB P06746 1/20 0.47
▸ TRPV1 Q8NER1 1/20 0.47
▸ HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12529014 0.90 MCHR1 (0.65) MCHR1CA12CA2CA9SMN1; SMN2
SCHEMBL12529006 0.88 SMN1; SMN2 (0.60) MCHR1SMN1; SMN2HTR1AHTR1DHTR1B
SCHEMBL12529075 0.88 HTR1A (0.62) MCHR1MAPTHTR1AHTR1DHTR1B
SCHEMBL12529071 0.88 MCHR1 (0.57) MCHR1CA12CA2CA9SMN1; SMN2
SCHEMBL12529009 0.87 MAPT (0.62) MCHR1CA12CA2CA9SMN1; SMN2
SCHEMBL12529055 0.86 MAPT (0.66) MCHR1CA12CA2CA9SMN1; SMN2
SCHEMBL12529074 0.85 MCHR1 (0.53) MCHR1SMN1; SMN2KDM4ELMNAHTR1A
SCHEMBL12529052 0.84 HTR1A (0.52) MCHR1CA12CA2CA9SMN1; SMN2
SCHEMBL12528767 0.84 MCHR1 (0.64) MCHR1CA12CA2CA9SMN1; SMN2
SCHEMBL12529081 0.83 POLB (0.52) MCHR1CA12CA2CA9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-06 — — US disclosed
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments CYP11B2, CYP11B1, NQO1 MCHR1 2068/4885CA12 2612/4885CA2 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback